Metriva is a company.
Key people at Metriva.
Metriva was founded by John Meissner (Entrepreneur and co-Founder).
No company named Metriva appears in the provided search results or aligns directly with the query. The closest matches are Mariva Capital Markets (a broker-dealer and asset management firm focused on global securities trading, bonds, stocks, and advisory services for institutions and high-net-worth individuals)[1][4] and MetaVia Inc. (a clinical-stage biotech company developing pharmaceuticals like DA-1241 and DA-1726 for cardiometabolic diseases, obesity, and related conditions)[6]. Metrica refers to a fund like Metrica Asia Event Driven Master Fund, but lacks substantive details[7].
Mariva, with over 70 years of experience rooted in Argentina and global reach via U.S. operations in Miami, specializes in investment services across 60+ markets, partnering with Pershing LLC (BNY Mellon) and StoneX. Its mission emphasizes fiduciary standards, long-term client relationships, and access to diverse products like sovereign debt from LatAm/emerging markets[1][4]. MetaVia, formerly NeuroBo Pharmaceuticals, targets unmet needs in metabolic disorders through agonists and analogs in Phase 1/2 trials, serving patients with type 2 diabetes, MASH, and obesity[6].
Mariva Capital Markets traces to an Argentine financial group with 70+ years in local/international capital markets, evolving into a U.S.-registered broker-dealer (FINRA/SEC member) with a Miami head office. Mariva Global Asset Management LLC was founded in 2019 in Florida, building on expertise in financial planning and portfolio management via partnerships like Pershing and Charles Schwab[1][4].
MetaVia Inc. rebranded from NeuroBo Pharmaceuticals in November 2024, headquartered in Cambridge, MA. It emerged from licensing deals, including with Pfizer for Gemcabene (dyslipidemia) and Dong-A ST for DA-1241/DA-1726 production. Early traction includes completed Phase 1 trials and ongoing Phase 2a for DA-1241 in MASH/type 2 diabetes[6].
Metrica appears tied to an Asia-focused event-driven hedge fund (Metrica Asia Event Driven Master Fund), with limited backstory beyond a 2017 newsletter[7].
Mariva operates in traditional finance rather than tech, riding trends in emerging market debt (LatAm focus) amid global capital flows and U.S. broker-dealer expansion. Timing benefits from post-2019 U.S. entity growth, supporting institutional trading in volatile regions like Argentina[1][4]. It influences ecosystems by providing liquidity to 300+ entities, though not tech-centric.
MetaVia, as a biotech (overlapping tech via drug development), taps the booming cardiometabolic market—driven by obesity/diabetes epidemics (e.g., GLP-1 agonists like those from Novo Nordisk/Eli Lilly). Market forces include rising Phase 1/2 trial demand and licensing for faster scaling. It contributes to the biotech ecosystem via innovative analogs addressing unmet needs in MASH and dual-agonists[6].
Mirova (possible misread as "Metriva") leads sustainable investing, directing capital to energy transition, equities, and private equity across asset classes, with $13.7B AUM as of June 2025[2][3][5]. This positions it in the green tech wave.
Without a clear Metriva, focus shifts to matches: Mariva may expand amid LatAm recovery, leveraging U.S. regs for more HNW/institutional flows, shaped by EM debt trends. MetaVia's outlook hinges on Phase 2a DA-1241 data; success could mirror GLP-1 booms, with obesity trials accelerating via partnerships—potentially evolving into a mid-cap player if milestones hit. Broader trends like sustainable finance (Mirova) and biotech innovation will amplify similar entities' influence, tying back to the query's intent on identifying niche financial/biotech players.
Metriva was founded by John Meissner (Entrepreneur and co-Founder).
Key people at Metriva.
